Jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC, in collaboration with the National Breast Cancer Foundation.

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Gilead Sciences, Inc.

DATE OF RELEASE/EXPIRATION

Monday, April 3, 2023 from 3:00-4:00pm ET

TARGET AUDIENCE

The primary target audience for this activity are breast oncologists and medical oncologists. The secondary audience for this activity are oncology pharmacists, oncology nurses, and oncology NPs/PAs.

STATEMENT OF NEED/PROGRAM OVERVIEW

Patients with HR+/HER2‐ metastatic breast cancer (MBC) are at increased risk of progression and adverse outcomes. While endocrine therapies are effective in early‐stage disease, patients with cancer that progresses to endocrine‐resistant disease have limited treatment options. Treatment can involve multiple chemotherapy regimens with high toxicity. However, additional therapeutic options are emerging for patients with HR+/HER2‐ MBC that has been heavily pretreated.

Join a panel of expert oncologists to discuss best practices for addressing treatment challenges for patients with heavily pretreated HR+/HER2‐ MBC. Panelists will share strategies for sequencing therapies in these patients and optimizing treatment in various patient subgroups. Recent data on emerging therapeutic options in this difficult‐to‐treat population will be reviewed, including novel antibody-drug conjugates (ADC) that have demonstrated efficacy in this population with reduced toxicity compared to chemotherapy.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Discuss available therapies for HR+/HER2- metastatic breast cancer, as well as the need for additional options for patients who progress despite previous treatment
• Apply evidence-based approaches for sequencing therapy in patients with HR+/HER2- metastatic breast cancer to maximize benefit and minimize toxicity
• Evaluate data for emerging agents that can have a clinically significant benefit for subgroups of patients with HR+/HER2- metastatic breast cancer, such as those with endocrine-resistant disease

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING EDUCATION

PACE designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

FACULTY AND DISCLOSURE OF CONFLICTS OF INTEREST

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty	Conflicts of Interest
Virginia Kaklamani, MD, DSc Professor of Medicine Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment A.B. Alexander Distinguished Chair in Oncology Leader, Breast Oncology Program Mays Cancer Center UT Health San Antonio, MD Anderson Cancer Center	Consultant, Advisor, Speaker: AstraZeneca, Daichi Sankyo, Genentech, Gilead, Lilly, Menarini, Pfizer, Seagen
Sara Tolaney, MD, MPH Chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers Associate Director, Susan F. Smith Center for Women’s Cancers Dana-Farber Cancer Institute Associate Professor of Medicine, Harvard Medical School	Advisory Board: 4D Pharm, ARC Therapeutics, Artios , iopharmaceuticals, BeyondSpring Pharmaceuticals, Incyte Corp, Myovant, Reveal Genomics, Umoja Biopharma, Zentalis, Zymeworks Consultant: Aadi Bio, Blueprint Medicines, CytomX, Daiichi Sankyo Consultant/Advisory Board: Menarini/Stemline Steering Committee: OncXerna Principle Investigator of Study: Cyclacel, Exelixis, Nanostring, Nektar Principle Investigator of Study/Consultant/Advisory Board: AstraZeneca, Bristol-Myers Squibb, Eisai, Genentech/Roche, Gilead, Merck, Novartis, Pfizer, Seattle Genetics Principle Investigator of Study/Consultant/Advisory Board/Steering Committee: Eli Lilly

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For additional information about the accreditation of this activity, please visit https://partnersed.com.

Technical Support:

For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.